Search Within

Linda Su Hyun Ahn

  1. "Radiology, Department of"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (17)
  2. Nursing (17)
  3. Radiology, Department of (17)
  4. Solid Tumor Oncology Division (17)
  5. GSK Faculty (15)
  6. Thoracic Oncology (15)

More Groups

People
  1. Charles Rudin (9)
  2. Paul Paik (9)
  3. Mark Kris (8)
  4. Andrew Plodkowski (7)
  5. Gregory Riely (7)
  6. Helena Yu (7)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (1)
  4. 2020 (3)
  5. 2019 (4)
  6. 2018 (5)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. Clinical Cancer Research (3)
  3. Journal of Thoracic Oncology (3)
  4. Cancer (1)
  5. Cold Spring Harbor Molecular Case Studies (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. American Medical Association (1)
  5. Cold Spring Harbor Laboratory Press (1)
  6. Elsevier BV (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations
    Journal Article

    Arbour, K. C.; Manchado, E.; Bott, M. J.; Ahn, L.; Tobi, Y.; Ni, A. A.; Yu, H. A.; Shannon, A.; Ladanyi, M.; Perron, V.; more...
    JTO Clinical and Research Reports (2022)

    Fulltext@MSK | Save
  • Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Plodkowski, A. J.; Fan, P. D.; Rudin, C. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers
    Journal Article

    Paik, P. K.; Kim, R. K.; Ahn, L.; Plodkowski, A. J.; Ni, A.; Donoghue, M. T. A.; Jonsson, P.; Villalona-Calero, M.; Ng, K.; McFarland, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Ginsberg, M. S.; Plodkowski, A. J.; Kim, R.; Doyle, L. A.; Rudin, C. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib and dacarbazine for leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors
    Journal Article

    D'Adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C. M.; Ezeoke, M. O.; Ahn, L.; Qin, L. X.; Antonescu, C. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save